Skip to main content
Trial Intelligence

Understand every study
before the first patient is enrolled.

Trial Intelligence reads your study, structures its design, and surfaces the operational, data, and execution risks that matter before enrollment begins.

It produces two deliverables: a free Executive Summary from a public ClinicalTrials.gov NCT, and a paid Study Intelligence Report from that same NCT or from your full protocol. Same engine, same rendered provenance, same versioned generation record.

Free from a public ClinicalTrials.gov NCT. Full-protocol analysis available through a 1-hour paid strategy session under NDA.

Executive Summary · Sample

Phase III Immunotherapy Plus Chemotherapy Studyin Advanced Non-Small-Cell Lung Cancer

NCT02****** · Global Oncology Sponsor

Phase
3
Enrollment
616
PTII™ v1
84/100
High Complexity
Protocol Complexity (PCI)
87
Operational Burden (OBI)
82
Eligibility Strictness (ESI)
71
Amendment Risk (ARI)
V2
Enrollment Velocity (EVI)
V2
Executive Bottom Line

Operational burden is driven by combination dosing logistics and tumor-tissue requirements during screening. Eligibility narrows the pool to recently diagnosed patients without prior systemic therapy.

Included in the Study Intelligence Report
Site network expansion recommended

Screening pool narrows sharply at community oncology sites; academic and tertiary sites recommended.

Recommendations, evidence citations & clickable provenanceTier 2 · Report
Generation Recordgenerated 2026-07-15engine CIE v1.2assessment PTII v1corpus 2026-07build v1.6.3
See the full sample artifact
The First View, Then the Complete Analysis

If we can do this from a ClinicalTrials.gov registry in minutes, imagine what the same platform does with your full protocol.

Start with the free Executive Summary. Go deeper with the Study Intelligence Report.

Tier 1 · Free

Executive Summary

A rapid, structured view a sponsor, CRO leader, or clinical-development executive uses to decide whether the study warrants deeper investigation.

Input: Public ClinicalTrials.gov NCT

  • Study identification and design overview
  • Phase, therapeutic area, enrollment, and countries
  • Complexity band: Low / Moderate / Elevated
  • Top operational risks and top data-management challenges
  • Estimated timeline range
  • Executive bottom line
  • Artifact source, generation date, engine version, assessment version, and platform build
  • Full source-cited risk analysisTier 2
  • CRF and SDTM domain recommendationsTier 2
  • PTII composite and contributing sub-indicesTier 2
  • Finding-level clickable provenanceTier 2
  • Reproducibility ID and independently versioned engine recordTier 2
Tier 2 · Paid

Study Intelligence Report

The complete analysis a clinical-development team can review and defend. Comprehensive, source-backed, and reproducible.

Input: NCT or full protocol

  • Everything in the Executive Summary
  • Full protocol analysis and source-cited risk breakdown
  • Operational burden and site complexity analysis
  • Visit schedule and endpoint analysis
  • CRF and SDTM domain recommendations
  • Statistical, monitoring, and submission-readiness considerations
  • PTII composite and contributing sub-indices
  • Every finding traceable to protocol section, engine version, evidence record, and source hash
  • Independently versioned engine and assessment record
  • Reproducibility ID for controlled re-generation

When you are ready to build, the Protocol Design Workspace (Tier 3) generates eCRFs, SDTM mapping, and the Schedule of Assessments from your protocol synopsis. The full PrismCDM Platform (Tier 4) runs the study to submission.

AI without provenance is difficult to trust. Clinical teams need to understand not only what AI recommends, but how it reached every conclusion.
The PrismCDM thesis
Early Access

Start with one study.

Generate a free Executive Summary from a ClinicalTrials.gov NCT in minutes. When you are ready, we walk through the full Study Intelligence Report on your protocol, every finding tied to its source, and show how the same platform continues through Protocol Design Workspace and the full PrismCDM Platform.